Differential roles of MAPK kinases MKK3 and MKK6 in osteoclastogenesis and bone loss. by Boyle, David L et al.
UC San Diego
UC San Diego Previously Published Works
Title
Differential roles of MAPK kinases MKK3 and MKK6 in osteoclastogenesis and bone loss.
Permalink
https://escholarship.org/uc/item/0js587xw
Journal
PloS one, 9(1)
ISSN
1932-6203
Authors
Boyle, David L
Hammaker, Deepa
Edgar, Meghan
et al.
Publication Date
2014-01-06
DOI
10.1371/journal.pone.0084818
 
Peer reviewed
eScholarship.org Powered by the California Digital Library
University of California
Differential Roles of MAPK Kinases MKK3 and MKK6 in
Osteoclastogenesis and Bone Loss
David L. Boyle1, Deepa Hammaker1*, Meghan Edgar1, Mario M. Zaiss2, Stefan Teufel3, Jean Pierre David3,
Georg Schett4, Gary S. Firestein1
1Medicine, University of California San Diego, La Jolla, California, United States of America, 2Global Health Institute, E´cole Polytechnique Fe´de`rale de Lausanne,
Switzerland, 3 Institute of Osteology and Biomechanics, University Medical Center Hamburg-Eppendorf, Hamburg, Germany, 4Department of Internal Medicine 3,
University of Erlangen-Nuremberg, Friedrich Alexander University, Erlangen, Germany
Abstract
Bone mass is maintained by osteoclasts that resorb bone and osteoblasts that promote matrix deposition and
mineralization. Bone homeostasis is altered in chronic inflammation as well as in post-menopausal loss of estrogen, which
favors osteoclast activity that leads to osteoporosis. The MAPK p38a is a key regulator of bone loss and p38 inhibitors
preserve bone mass by inhibiting osteoclastogenesis. p38 function is regulated by two upstream MAPK kinases, namely
MKK3 and MKK6. The goal of this study was to assess the effect of MKK3- or MKK6-deficiency on osteoclastogenesis in vitro
and on bone loss in ovariectomy-induced osteoporosis in mice. We demonstrated that MKK3 but not MKK6, regulates
osteoclast differentiation from bone marrow cells in vitro. Expression of NFATc1, a master transcription factor in
osteoclastogenesis, is decreased in cells lacking MKK3 but not MKK6. Expression of osteoclast-specific genes Cathepsin K,
osteoclast-associated receptor and MMP9, was inhibited in MKK32/2 cells. The effect of MKK-deficiency on ovariectomy-
induced bone loss was then evaluated in female WT, MKK32/2 and MKK62/2 mice by micro-CT analysis. Bone loss was
partially inhibited in MKK32/2 as well as MKK62/2 mice, despite normal osteoclastogenesis in MKK62/2 cells. This
correlated with the lower osteoclast numbers in the MKK-deficient ovariectomized mice. These studies suggest that MKK3
and MKK6 differentially regulate bone loss due to estrogen withdrawal. MKK3 directly mediates osteoclastogenesis while
MKK6 likely contributes to pro-inflammatory cytokine production that promotes osteoclast formation.
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Introduction
Homeostatic maintenance of bone mass and strength requires
the concerted actions of bone-forming osteoblasts and bone-
resorbing osteoclasts [1]. Imbalances in bone remodeling that
favor osteoclast differentiation, survival and activation occur in
chronic inflammatory diseases such as rheumatoid arthritis (RA) as
well as in post-menopausal osteoporosis [2,3]. Pro-inflammatory
cytokines such as IL-1, TNF, and IL-6 in chronic inflammation or
the loss of estrogen in menopause regulate bone resorption by
increasing the expression of Receptor Activator of NF-kB ligand
(RANKL) on osteoblasts and stromal cells or by amplifying
RANKL-mediated differentiation of monocytes to osteoclasts [4–
7]. The interaction of RANKL with its cognate receptor RANK,
expressed on osteoclasts, initiates signaling that enhances osteo-
clast activity, leading to accelerated bone loss and fractures [8].
RANK and RANKL belong to the TNF receptor superfamily
[9,10]. The binding of RANKL to RANK recruits the adapter
protein TNF receptor associated factor-6 (TRAF6) to the plasma
membrane [11]. RANK, RANKL, and TRAF6 are essential for
osteoclastogenesis as mice lacking these molecules have profound
defects in bone resorption [11]. The RANK/TRAF6 complex
activates several pathways including NF-kB and the MAPKs, JNK
and p38, which induce the expression of NFATc1, considered one
of the master transcription factors of osteoclastogenesis [12,13].
NFATc1, in conjunction with the transcription factors AP-1, PU.1
and micropthalmia transcription factor (MITF), is required for the
expression of osteoclast specific genes such as tartrate-resistant acid
phosphatase (TRAP) and Cathepsin K that promote bone
resorption and demineralization [14,15].
The p38 family of MAPKs, most notably p38a, is an essential
regulator of RANKL-mediated osteoclastogenesis, which makes it
a potential therapeutic target for osteoporosis [16]. Several studies
have shown that p38 inhibitors prevented inflammatory bone
destruction in animal models and in some cases, reversed the
existing disease [17–19]. MAPK kinases, MKK3 and MKK6, are
two upstream enzymes that differentially regulate p38 function
[20]. Our previous studies have shown that MKK3 is required for
optimal p38a activation while MKK6 regulates pro-inflammatory
cytokine production in response to LPS and TNF [21]. In
addition, either MKK3- or MKK6-deficiency reduces arthritis
severity and joint destruction in passive serum transfer K/BxN
arthritis or collagen-induced arthritis [21–23]. The goal of this
study was to assess the role of MKK3 and MKK6 in p38-regulated
bone resorption. Therefore, we evaluated the effect of MKK3-
and MKK6-deficiency on osteoclastogenesis in vitro and on bone
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preservation in vivo using an ovariectomy model of osteoporosis.
These studies show that blocking either MKK3 or MKK6 has
beneficial effects on bone preservation by differentially regulating
osteoclastogenesis or function.
Materials and Methods
Mice
Female wildtype (WT) C57Bl/6 mice (6–8 weeks old) were
purchased from Charles River Laboratories (Wilmington, MA).
Female MKK32/2 and MKK62/2 mice (C57Bl/6 back-
ground) were obtained from Dr. Richard Flavell (Yale University,
CT).
Ethics Statement
All experimental animal protocols were reviewed and approved
by the University of California San Diego Institutional Animal
Care and Use Committee. This study was carried out in strict
accordance with the recommendations in the Guide for the Care
Figure 1. Effect of MKK-deficiency in osteoclastogenesis in vitro. (A) WT, MKK32/2 and MKK62/2 bone marrow cells were cultured to
induce osteoclastogenesis and analyzed by TRAP staining (n = 3/group). The number of osteoclasts were counted in 5 pre-defined locations per well
and the data are represented as mean 6 SEM. Numbers of osteoclasts were reduced in SB-treated WT and MKK32/2 cells compared with WT.
Osteoclastogenesis in MKK62/2 group were comparable to WT cells. *p,0.05 (B) Phosphorylation of p38 in MKK-deficient osteoclasts. Western blot
analysis showed that P-p38 levels were significantly lower in MKK32/2 but not in MKK62/2 compared with WT group. *p,0.05.
doi:10.1371/journal.pone.0084818.g001
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and Use of Laboratory Animals of the National Institutes of
Health. All surgeries were performed under isoflurane vaporizer,
and all efforts were made to minimize suffering. Mice were housed
using standard housing conditions and allowed access to food and
water ad libitum.
Generation of Osteoclasts
Bone marrow was isolated from WT, MKK32/2, and
MKK62/2 femora and tibias. The red blood cells were lysed
and the remaining cells were counted and seeded in T75 flasks at
16106 cells/ml. The cells were cultured for 24 h in aMEM (1X)
containing GlutaMAX (Invitrogen, Carlsbad, CA) supplemented
with 10% FBS, 5% penicillin-streptomycin, and 30 ng/ml of
recombinant murine M-CSF (Peprotech, Rocky Hill, NJ). After 24
hours, the non-adherent cells were seeded in 24-well plates (16106
cells/ml) with 30 ng/ml of M-CSF and 50 ng/ml of receptor
activator of NF-kB ligand (RANKL) (R&D, Minneapolis, MN).
The culture medium was replaced every 72 h and supplemented
with M-CSF and RANKL for 5–8 days until multinucleated
osteoclasts were observed. In some experiments, cells were
cultured for 5 days with 3 mM SB203580 (p38 inhibitor) or
DMSO (EMD Chemicals, Gibbstown, NJ).
Osteoclast Differentiation and Activity
Tartrate-resistant acid phosphatase (TRAP) staining: Differen-
tiated cells were stained using the Acid Phosphatase, Leukocyte
(TRAP) kit (Sigma-Aldrich, St. Louis, MO). Osteoclasts were
defined as multinucleated ($3 nuclei), TRAP positive cells and
were counted in 5 pre-defined locations in each well. The data are
represented as average count in each well.
Bone resorption assay: Bone marrow monocytes (BMM) were
seeded at 36105 cells/well for 8 days on an OsteologicTM Bone
Cell Culture System (BD BiocoatTM, Bedford, MA) (4). The cell
culture system was then subjected to von Kossa staining. Eight
defined areas of each well were imaged and the resorption pits
were quantified using Image Pro Plus software (Media Cybernet-
ics, Bethesda, MD). The average resorption was calculated per
area for each well and the data are expressed as a percentage of
resorbed area/total area.
Ovariectomy
At 16 weeks of age, female WT, MKK32/2, and MKK62/2
mice were subjected to ovariectomy or sham-surgery and allowed
to recover for 6 weeks. To confirm ovariectomy, leutinizing
hormone (LH) was measured in serum by sandwich ELISA
(Ligand assay and analysis core lab at the University of Virginia).
Micro-Computed Tomography (micro-CT) and Bone
Histomorphometry
Micro-CT images of the tibias were acquired as described
previously [13]. Briefly, the tibias were harvested, fixed in 10%
neutral buffered formalin for 24 h and stored in 70% ethanol. All
quantifications were performed with digital image analysis
(OsteoMeasure; Osteometrics, Atlanta, GA). The following
parameters were measured: fraction of bone volume of the total
Figure 2. Bone resorption by MKK3- and MKK6-deficient osteoclasts. WT, MKK32/2 and MKK62/2 bone marrow cells were differentiated
into osteoclasts on a calcium matrix and subjected to Von Kossa staining to determine resorption activity. The resorption pit area was calculated in
eight areas/well and data are shown as percent resorbed area/total area. Resorption activity was significantly reduced in MKK32/2 but not MKK62/
2 osteoclasts compared with WT. n = 3/group, *p,0.05.
doi:10.1371/journal.pone.0084818.g002
MKK3 and MKK6 in Osteoclastogenesis and Bone Loss
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sample volume (bone volume/tissue volume (BV/TV)), trabecular
number (Tb.N), trabecular thickness (Tb.Th), and trabecular
separation (Tb.Sp).
Histomorphometric analysis was performed on methacrylate-
embedded undecalcified plastic sections of bone and were stained
using von Kossa’s stain and TRAP stain. To measure bone
formation rate (BFR), all mice were injected with calcein green
solution (30 mg/kg, Sigma, MO) at 10 days and 2 days prior to
harvesting. The tibias were prepared as described above and the
measurements were performed using an image analysis system
(OsteoMeasure) and the bone formation rate was calculated and
the data are shown as mm3/mm2/year.
Gene Expression Analysis
Total RNA was isolated from cells and 500 ng RNA was used
for first-strand cDNA synthesis (Life Technologies, NY). Quanti-
tative real-time PCR was performed using Taqman gene
expression assay primer/probe sets and GeneAmp 7300 system
(Applied Biosystems, Foster City, CA) [24]. Ct values were
normalized to hypoxanthine-guanine phosphoribosyl transferase 1
(Hprt1) using the DDCt method.
Western Blot Analysis
Osteoclasts were lysed using a lysis buffer containing 50 mM
HEPES (pH 7.4), 150 mM NaCl, 25 mM MgCl2, 1 mM EDTA
Figure 3. Gene expression in MKK32/2 and MKK62/2 osteoclasts. WT, MKK32/2 and MKK62/2 osteoclast RNA was isolated and
subjected to qPCR using gene-specific primer probe sets (n = 3/group). Expression of NFATc1, cFos, Cathepsin K, OSCAR and MMP9 was significantly
lower in MKK32/2 but not MKK62/2 cells, compared with WT. RANK expression was comparable in WT, MKK32/2 and MKK62/2 groups. *p,0.05.
doi:10.1371/journal.pone.0084818.g003
MKK3 and MKK6 in Osteoclastogenesis and Bone Loss
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(pH8.0), 10% glycerol, 1% Triton X-100, 20 mM ß-glycerophos-
phate, 10 mM NaF, 1 mM Na2VO4, 0.4% cocktail protease
inhibitor (Roche, Indianapolis, IN). Protein was quantified using a
Micro BCA protein assay kit (Thermo Scientific, Waltham, MA)
and separated using a NupageH Bis-Tris 4–12% polyacrylamide
gel (Invitrogen) and transferred onto a PVDF membrane. The
membrane was probed with antibodies specific for mouse
phospho-p38 (Sigma), total p38 (Cell Signaling Technology,
Danvers, MA), and Actin (Sigma, MO). Western blots were
developed using the Immun-starTM Western C Kit and images
were analyzed using the Versadoc Imaging System and Quantity
One software (Bio-Rad Laboratories, Hercules, CA).
Statistical Analysis
Comparisons between WT, MKK32/2, and MKK62/2
cells were analyzed by one-way ANOVA and Tukey’s or Kruskal-
Wallis multiple comparison tests, unless otherwise stated. Ovari-
ectomy data were analyzed by two-way ANOVA and Tukey’s
multiple comparison test. Data were analyzed using GraphPad
Figure 4. Ovariectomy-induced bone loss in MKK32/2 and MKK62/2 mice. (A) WT, MKK32/2 and MKK62/2 mice were subjected to
ovariectomy and bone loss was calculated using micro-CT analysis (n = 5/group). Representative images are shown. Significant bone loss was
observed in all three groups. (B) Bone volume and trabecular number were elevated in MKK32/2 and MKK62/2 sham-treated or OVX mice
compared with respective WT controls. Trabecular thickness was similar in sham-treated and OVX mice. Trabecular separation was significantly higher
in WT and MKK32/2 mice after OVX. MKK3- and MKK6-deficient mice had high bone mass phenotype compared with WT in sham-treated or OVX
groups.
doi:10.1371/journal.pone.0084818.g004
MKK3 and MKK6 in Osteoclastogenesis and Bone Loss
PLOS ONE | www.plosone.org 5 January 2014 | Volume 9 | Issue 1 | e84818
Prism 6.0 and the comparisons were considered statistically
significant if p,0.05.
Results
Effect of MKK3- and MKK6-deficiency on
Osteoclastogenesis in vitro
To evaluate the role of MKK3 and MKK6 in osteoclast
differentiation, we cultured WT and MKK3- and MKK6-
Figure 5. Histomorphometric analysis of bone in ovariectomized MKK32/2 and MKK62/2mice. (A) Tibial bone sections from sham and
OVX-treated mice were stained and representative figures are shown (n= 5/group) (B) Histomorphometric analysis showed that bone volume and
trabecular number were elevated in MKK62/2 mice compared with WT after sham surgery or OVX. Trabecular thickness was unaltered after OVX in
the three groups. TRAP-staining showed lower osteoclast numbers (NOc/B.Pm) after OVX in MKK32/2 and MKK62/2 compared with WT mice.
Osteoblast numbers were unaltered after OVX in the three groups. (C) Bone formation rate was evaluated by injecting mice with calcein green
solution at 10 days and 2 days prior to harvesting. The tibias were evaluated for bone formation rate (n = 3/group). Bone formation rate was unaltered
by MKK-deficiency in sham- or OVX-treated mice compared with WT controls. *p,0.05.
doi:10.1371/journal.pone.0084818.g005
MKK3 and MKK6 in Osteoclastogenesis and Bone Loss
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deficient bone marrow cells in the presence of M-CSF and
RANKL. WT cells were cultured in the presence or absence of the
p38 inhibitor SB203580 (SB). Osteoclastogenesis was significantly
decreased in MKK32/2 (p = 0.0012) and SB-treated WT group
(p,0.0001) compared with WT control (Figure 1A, n= 3 mice/
group). MKK32/2 osteoclast numbers were also significantly
lower than MKK62/2 cells (p = 0.0012). Surprisingly, osteoclast
numbers in MKK62/2 group were comparable to the WT
control. We next determined the level of phosphorylation of p38
(P-p38) in cultured WT, MKK32/2 and MKK62/2 osteoclasts
by Western blot analysis. MKK32/2 cells had significantly
reduced P-p38 levels compared with WT or MKK62/2
(Figure 1B, p = 0.0009 and p= 0.005, respectively). These data
show that MKK3, but not MKK6, is an important regulator of
osteoclast differentiation in vitro.
Bone Resorption Activity in MKK3- and MKK6-deficient
Osteoclasts
Bone resorption of MKK-deficient osteoclasts was then
determined by their ability to demineralize matrix and form
resorption pits. Resorption was visualized using Von Kossa
staining (Figure 2). MKK32/2 osteoclasts had a significantly
lower number of resorptive pits than WT (p= 0.0061) or
MKK62/2 cells (p = 0.027, Kruskal-Wallis test), suggesting that
MKK3 is a key regulator of osteoclast differentiation in vitro.
Gene Expression in MKK32/2 and MKK62/2
Osteoclasts
Osteoclast differentiation requires the expression of a number of
well-characterized markers such as NFATc1 and Cathepsin K,
which regulate osteoclast function. To determine the effect of
MKK-deficiency on these markers, we compared gene expression
in WT, MKK32/2, and MKK62/2 osteoclasts by qPCR
(Figure 3). Expression of Cathepsin K and osteoclast-associated
receptor (OSCAR) was significantly reduced in MKK32/2
osteoclasts compared with WT (p,0.001, respectively) or
MKK62/2 cells (p,0.001, respectively). Similarly, NFATc1
expression was significantly reduced in MKK32/2 cells com-
pared with WT (p= 0.004) or MKK62/2 osteoclasts (p = 0.009).
Expression of c-fos and MMP9 (gelatinase B) was inhibited only in
MKK32/2 cells (p = 0.037 and p= 0.031, respectively, t-test)
compared with WT. In contrast, RANK expression was not
decreased in MKK-deficient cells. These data show that in vitro
expression of osteoclast-specific markers is inhibited in the absence
of MKK3.
Ovariectomy-induced Bone Loss in MKK3- and MKK6-
deficient Mice
Loss of estrogen in ovariectomized (OVX) mice is associated
with increased bone turnover with bone resorption exceeding
formation, leading to a net bone loss. Thus far, our data have
shown that MKK3-deficiency decreases osteoclastogenesis and
bone resorption in vitro, suggesting that a lack of MKK3 might
preserve bone in vivo. We therefore examined the effect of MKK-
deficiency on bone preservation after ovariectomy. The efficiency
of the surgery was confirmed by showing increased levels of
luteinizing hormone (LH) in post-surgical sera (Figure S1).
Trabecular bone density at the proximal tibia was evaluated in
OVX or sham control mice using micro-CT (Figure 4A, n = 5/
group).
Micro-CT analysis showed significantly higher bone volume
(BV/TV) and trabecular number (Tb.N.) in sham MKK32/2
mice compared with WT sham control (Figure 4B, BV: p= 0.003,
Tb.N: p= 0.006). Surprisingly, sham MKK62/2 mice had a
significantly elevated bone volume and Tb.N. compared with
sham WT control (BV: p,0.0001, Tb.N: p,0.0001). Together,
these data suggest that both MKK3 and MKK6 play a role in
physiological bone homeostasis. While a significant bone loss was
observed after OVX in all three genotypes, bone volume and
Tb.N were modestly elevated in OVX MKK32/2 and
significantly increased in MKK62/2 mice compared to the
OVX WT control. These results suggest that MKK62/2 mice
were partially protected from OVX-mediated bone loss, main-
taining a bone volume similar to sham-treated WT controls.
Trabecular thickness was virtually unchanged in OVX or sham
control WT and MKK2/2 mice. In contrast, trabecular
separation (Tb. Sp) was significantly higher after OVX in WT
(p= 0.002) and MKK32/2 (p = 0.005) but not in MKK62/2,
compared with their respective sham controls. Trabecular
separation was significantly lower in OVX MKK32/2
(p = 0.003) and MKK62/2 (p,0.0001) compared with OVX
WT mice, indicating a higher bone mass in MKK-deficient mice.
Together, the in vivo data demonstrate that MKK3- and MKK6-
deficiency are associated with a high bone mass phenotype, which
is partially maintained after OVX.
Histomorphometric Analysis of Bone in Ovariectomized
MKK3- and MKK6-deficient Mice
To further evaluate the effect of MKK3- and MKK6-deficiency
in estrogen-deficient mice, undecalcified tibial bone sections from
OVX and sham control mice were stained and subjected to
histomorphometric analysis (Figure 5A, B). Consistent with the
micro-CT data, bone volume (%BV/TV) was significantly higher
in sham- and OVX-treated MKK32/2 (p,0.05 for each) and
MKK62/2 mice compared to respective WT controls (p,0.001,
for each). OVX led to a reduction of bone volume in the WT,
MKK32/2 and MKK62/2 groups (n = 5/treatment, p,0.001,
respectively). Nonetheless, bone volume and trabecular number
were at least partially maintained in MKK-mutants, indicating a
similar bone volume after OVX as sham-treated WT mice.
Trabecular thickness (Tb.Th) was similar in WT, MKK32/2,
and MKK62/2 mice, both after sham-treatment and OVX.
TRAP staining showed higher osteoclast numbers (NOc/bone
perimeter) in OVX WT mice compared with sham-treated WT
mice (p,0.001). However, MKK3- and MKK6-deficient mice
had significantly lower osteoclast numbers compared with sham-
treated or OVX WT mice (MKK32/2: p,0.01, MKK62/
2:p,0.001). Interestingly, the number of osteoblasts (NOb) and
bone formation rate was not altered in MKK3 and MKK6
mutants. These results suggest that MKK-deficiency inhibits
osteoclast formation in vivo but does not alter numbers of
osteoblasts or bone formation (Figure 5C). Together, these data
show that MKK-deficiency induced high bone mass by lowering
osteoclast numbers in vivo.
Discussion
Osteoclast differentiation and activation is regulated by p38
MAPK, at least in part by mediating the effects of pro-
inflammatory cytokines [25,26]. Several studies have shown that
p38 inhibitors protect against bone resorption in inflammation,
possibly through the direct effects on osteoclasts as well as through
inhibition of p38-induced cytokine expression. For instance, p38a
activation is essential for TNF-mediated inflammatory bone loss,
and a selective p38a inhibitor prevented trabecular bone loss and
increased cortical bone area in ovariectomized rats [13,27]. Our
previous studies demonstrated clinical benefits of MKK3- and
MKK3 and MKK6 in Osteoclastogenesis and Bone Loss
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MKK6-deficiency in acute and chronic models of arthritis [21–
23]. Inflammation-induced bone loss in the joints was markedly
reduced in the absence of MKK3 or MKK6, with a corresponding
decrease in serum IL-6 and synovial MMP [22]. In the present
study, we extend our observations on bone protection by
evaluating the effect of MKK3- and MKK6-deficiency on
osteoclastogenesis and bone loss due to estrogen withdrawal in
ovariectomized mice.
Our data show that MKK3 and MKK6 differentially regulate
osteoclastogenesis. MKK3 is required for optimal osteoclastogen-
esis and function. MKK6 was unable to effectively compensate for
the absence of MKK3 in the osteoclasts. MKK6-deficiency, on the
other hand, did not affect osteoclastogenesis in vitro. Consistent
with our previous studies, P-p38 levels were markedly reduced in
MKK32/2 but normal in MKK62/2 osteoclasts [21]. Oste-
oclast numbers and resorption activity correlated with p38
activation in MKK32/2 and MKK62/2 cells and are in
agreement with previous studies [16]. Expression of NFATc1 and
c-fos were reduced in MKK32/2 osteoclasts, indicating that p38
function is necessary for the induction of these transcription factors
that are involved in osteoclast differentiation [28]. Cathepsin K,
OSCAR, and matrix metalloproteinase 9 (MMP9) expression was
reduced in MKK3-deficient osteoclasts. This is consistent with the
requirement of NFATc1 in the transcription of these osteoclast-
specific markers [15,29,30]. Together, these results indicate that
MKK3, rather than MKK6, is a principal regulator of RANKL-
induced signaling in osteoclastogenesis in vitro. These data are in
accordance with other studies showing that p38 regulates the early
phases of osteoclast differentiation [31,32]. However, those studies
suggested that MKK6, but not MKK3, is necessary for
osteoclastogenesis in vitro, where it enhances cell survival but
not bone resorption. The differences might be partly due to
differences in the methodology, such as the efficiency of inhibiting
MKK3 and MKK6 using viral transduction of dominant-negative
MKK3 and MKK6 constructs compared with using bone
marrow-derived osteoclasts of MKK32/2 and MKK62/2
mice.
Osteoclastogenesis in vivo is regulated by a number of factors
such as vitamin D, parathyroid hormone, prostaglandins and most
notably, estrogen [33–36]. Estrogen is a key modulator of both the
immune system and bone homeostasis [37]. It regulates bone
remodeling by decreasing osteoclast life span by promoting
apoptosis [38,39]. Estrogen inhibits expression of RANKL on
osteoblasts, stromal cells, and lymphocytes, and increases produc-
tion of osteoprotegerin (OPG), an inhibitor of RANK signaling
[1]. In menopause, the loss of estrogen is associated with elevated
levels of IL-1, IL-6, TNF, and M-CSF, which support bone
resorption [40,41]. Estrogen deficiency also triggers the differen-
tiation of Th17 cells that produce the pro-inflammatory cytokine
IL-17 [42]. IL-17 induces osteoblast and stromal cell production of
IL-6, and TNF, which induce RANKL expression, accelerate
osteoclastogenesis and lead to osteoporosis [43].
In this study, we showed that both MKK3- and MKK6-
deficiency is associated with high bone mass and at least partially
inhibited bone loss after ovariectomy, even though our in vitro
studies did not show major effects of MKK6 on in vitro
osteoclastogenesis. Histomorphometric data demonstrated that
high bone mass in MKK3 and MKK6-deficiency correlates with
reduced osteoclast numbers. The decrease in osteoclast numbers in
MKK6-deficient mice could be due to decreased p38-regulated
cytokine production, such as IL-6, since a direct effect on
osteoclasts was not observed. The bone protection is consistent
with our previous studies showing reduced inflammation and joint
destruction in MKK32/2 and MKK62/2 mice, where a direct
effect on osteoclasts for MKK3 and an indirect effect by blocking
cytokines for MKK6 were found [22].
The study also found no major effect on osteoblast number and
bone formation rate in MKK3- and MKK6- deficient mice. The
regulation of bone homeostasis and skeletal formation was recently
evaluated in MKK3- and MKK6-deficient mice [44]. That study
showed that both MKK32/2 and MKK62/2 mice had
reduced bone mass resulting from defective osteoblast differenti-
ation. The reason for the discrepancy is unclear but might be
partly due to strain variations in mice and the different ages of the
mice used, 5 weeks compared with 20 weeks for our study.
In conclusion, MKK3 and MKK6 affect bone mass through
regulation of osteoclast numbers in vivo. MKK6 and to a lesser
extent MKK3 mitigate bone loss in conjunction with estrogen
deficiency. While MKK3 likely mediates direct effects on
osteoclasts through RANKL signaling, MKK6 likely contributes
to the production of pro-inflammatory cytokines such as IL-6 and
IL-17 that increase RANKL expression. Targeting upstream p38
kinases, such as MKK3 and MKK6 might modulate bone loss
during inflammation and estrogen deficiency.
Supporting Information
Figure S1 Serum leutinizing hormone (LH) in ovariec-
tomized mice. The efficiency of the ovariectomy was evaluated
by measuring LH in sera. LH levels were significantly elevated in
ovariectomized WT, MKK32/2, and MKK62/2 sera com-
pared with sham-treated sera (n = 8/group, *p,0.05).
(TIF)
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